Salvage lopinavir-ritonavir therapy in human immunodeficiency virus-infected children

Pediatric Infectious Disease Journal

Volumn 23, Issue 10, 2004, Pages 923-930

  Resino, Salvador ^a   Bellón, José Maria ^a   Ramos, José Tomás ^b   Navarro, Maria Luisa ^a   Martín Fontelos, Pablo ^c   Cabrero, Esther ^d   Muñoz Fernández, Maria Ángeles ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^d ABBOTT LABORATORIES   (Spain)

Author keywords

Children; Human immunodeficiency virus type 1; Lopinavir ritonavir; Salvage therapy; Viral load

Indexed keywords

AMPRENAVIR; EFAVIRENZ; INDINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; LOPINAVIR; PYRIMIDINONE DERIVATIVE;

ARTICLE; CHILD; CONTROLLED STUDY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SALVAGE THERAPY; TREATMENT OUTCOME; VIRUS LOAD; AMINO ACID SEQUENCE; ANTIBIOTIC RESISTANCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; DRUG EFFECT; GENETICS; GENOTYPE; MULTICENTER STUDY; MUTATION; VIRUS GENE;

AMINO ACID SEQUENCE; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; GENES, VIRAL; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MUTATION; PYRIMIDINONES; RITONAVIR; SALVAGE THERAPY; VIRAL LOAD;

EID: 16544384038     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000142170.52155.7f     Document Type: Article

References (43)

1. de Martino M, Tovo PA, Balducci M, et al. Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection: Italian Register for HIV Infection in Children and the Italian National AIDS Registry. JAMA. 2000;284:190-197.
2. Luzuriaga K, Bryson Y, Krogstad P, et al. Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection. N Engl J Med. 1997;336:1343-1349.
3. Kline MW, Fletcher CV, Harris AT, et al. A pilot study of combination therapy with indinavir, stavudine (d4T), and didanosine (ddl) in children infected with the human immunodeficiency virus. J Pediatr. 1998;132: 543-546.
4. Melvin AJ, Rodrigo AG, Mohan KM, et al. HIV-1 dynamics in children. J Acquir Immune Defic Syndr Hum Retrovirol. 1999;20:508-513.
5. Hirsch MS, Conway B, D'Aquila RT. et al. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society-USA Panel. JAMA. 1998;279: 1984-1991.
6. Aleman S, Soderbarg K, Visco-Comandini U, Sitbon G, Sonnerborg A. Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy. AIDS. 2002;16:1039-1044.
7. Spector SA, Hsia K, Yong FH, et al. Patterns of plasma human immunodeficiency virus type 1 RNA response to highly active antiretroviral therapy in infected children. J Infect Dis. 2000;182:1769-1773.
8. Shearer WT, Quinn TC, LaRussa P, et al. Viral load and disease progression in infants infected with human immunodeficiency virus type 1: Women and Infants Transmission Study Group. N Engl J Med. 1997;336:1337-1342.
9. Watson DC, Farley JJ. Efficacy of and adherence to highly active antiretroviral therapy in children infected with human immunodeficiency virus type 1. Pediatr Infect Dis J. 1999; 18:682-689.
10. Starr SE, Fletcher CV, Spector SA, et al. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse- transcriptase inhibitors in children infected with human immunodeficiency virus type 1: Pediatric AIDS Clinical Trials Group 382 Team. N Engl J Med. 1999;341:1874-1881.
11. Walmsley S. Individualized therapy for the treatment-experienced patient. AIDS Read. 2003;13:S11-S15.
12. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med. 2002;346:2039-2046.
13. Saez-Llorens X, Violari A, Deetz CO, et al. Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children. Pediatr Infect Dis J. 2003;22:216-224.
14. Benson CA, Deeks SG, Brun SC, et al. Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients. J Infect Dis. 2002;185: 599-607.
15. Kempf DJ, Isaacson JD, King MS, et al. Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. J Virol. 2001;75: 7462-7469.
16. Monno L, Saracino A, Scudeller L, et al. HIV-1 phenotypic susceptibility to lopinavir (LPV) and genotypic analysis in LPV/r-naive subjects with prior protease inhibitor experience. J Acquir Immune Defic Syndr. 2003;33:439-447.
17. Kempf DJ, Isaacson JD, King MS, et al. Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy. Antivir Ther. 2002;7:165-174.
18. Bongiovanni M, Bini T, Adorni F, et al. Virological success of lopinavir/ ritonavir salvage regimen is affected by an increasing number of lopinavir/ritonavir-related mutations. Antivir Ther. 2003;8:209-214.
19. de Mendoza C, Martin-Carbonero L, Barreiro P, et al. Salvage treatment with lopinavir/ritonavir (Kaletra) in HIV-infected patients failing all current antiretroviral drug families. HIV Clin Trials. 2002;3:304-309.
20. Corbett AH, Lim ML, Kashuba AD. Kaletra (lopinavir/ritonavir). Ann Pharmacother. 2002;36:1193-1203.
21. Munoz-Fernandez MA, Obregon E, Navarro J, et al. Relationship of virologic, immunologic, and clinical parameters in infants with vertically acquired human immunodeficiency virus type 1 infection. Pediatr Res. 1996;40:597-602.
22. Hirsch MS, Brun-Vezinet F, D'Aquila RT, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA. 2000;283:2417-2426.
23. Centers for Disease Control and Prevention. Guidelines for use of antiretroviral agents in pediatric HIV infection. MMWR. 1998;47:1-43.
24. Centers for Disease Control and Prevention. Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR CDC Surveill Summ. 1994;43:1-10.
25. Sharland M, Gibb D, Giaquinto C. Current evidence for the use of paediatric antiretroviral therapy: a PENTA analysis. Paediatric European Network for the Treatment of AIDS Steering Committee. Eur J Pediatr. 2000;159:649-656.
26. + T-cells response to HAART in HIV-infected children: an observational study. Clin Infect Dis. 2003;37:1216-1225.
27. Purswani M, Johann-Liang R, Cervia J, Noel GJ. Effect of changing antiretroviral therapy on human immunodeficiency virus viral load: experience with fifty-four perinatally infected children. Pediatr Infect Dis J. 1999;18:512-516.
28. Rutstein RM, Feingold A, Meislich D, Word B, Rudy B. Protease inhibitor therapy in children with perinatally acquired HIV infection. AIDS. 1997;11:F107-F111.
29. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med. 1999;131:81-87.
30. Loutfy MR, Walmsley SL. Salvage antiretroviral therapy in HIV infection. Expert Opin Pharmacother. 2002;3:81-90.
31. Young B, Kuritzkes DR. Viral kinetics: implications for treatment. AIDS. 1999;13:S11-S17.
32. Larder BA, Kemp SD. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Proc Natl Acad Sci U S A. 1989;86:9514-8.
33. Sharland M, di Zub GC, Ramos JT, Blanche S, Gibb DM. PENTA guidelines for the use of antiretroviral therapy in paediatric HIV infection. Pediatric European Network for Treatment of AIDS. HIV Med. 2002;3:215-226.
34. Cvetkovic RS, Goa KL. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs. 2003;63:769-802.
35. Boffito M, Arnaudo I, Raiteri R, et al. Clinical use of lopinavir/ritonavir in a salvage therapy setting: pharmacokinetics and pharmacodynamics. AIDS. 2002;16:2081-2083.
36. Gilleece YC, Qazi NA, Morlese JF, et al. The efficacy of lopinavir in individuals experiencing protease inhibitor failure. J Acquir Immune Defic Syndr. 2003;32:238-240.
37. Mocroft A, Phillips AN, Miller V, et al. The use of and response to second-line protease inhibitor regimens: results from the EuroSIDA study. AIDS. 2001;15:201-209.
38. Nadal D, Steiner F, Cheseaux JJ, et al. Long-term responses to treatment including ritonavir or nelfinavir in HIV-1-infected children. Pediatric AIDS Group of Switzerland. Infection. 2000;28:287-296.
39. Staszewski S, Miller V, Sabin C, et al. Virological response to protease inhibitor therapy in an HIV clinic cohort. AIDS. 1999;13:367-373.
40. Mocroft A, Devereux H, Kinloch-de-Loes S, et al. Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic population. Royal Free Centre for HIV Medicine. AIDS. 2000;14:1545-1552.
41. Mocroft A, Gill MJ, Davidson W, Phillips AN. Predictors of a viral response and subsequent virological treatment failure in patients with HIV starting a protease inhibitor. AIDS. 1998;12:2161-2167.
42. Prado JG, Wrin T, Beauchaine J, et al. Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity. Aids. 2002;16:1009-1017.
43. Tsuchiya K, Matsuoka S, Hachiya A, et al. Accumulation of lopinavir resistance-associated mutations over 3 years follow-up of patients on highly active antiretroviral therapy: implication in salvage therapy. AIDS. 2001;15:1183-1184.